Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (NASDAQ: ACET) operates at the forefront of allogeneic cell therapy development, making its news flow particularly relevant for investors tracking the gamma delta T cell therapeutic space. As a clinical-stage biotechnology company, Adicet generates news around clinical trial milestones, regulatory interactions, and scientific data presentations that can significantly impact market perception.
News coverage for Adicet Bio typically centers on clinical development updates, including patient enrollment announcements, preliminary efficacy and safety data readouts, and dosing milestones across its oncology and autoimmune disease programs. These updates provide visibility into the company's progress toward potential regulatory submissions and commercial viability.
Financial and corporate developments also feature prominently in Adicet's news cycle. As a pre-revenue biotechnology company, equity financing announcements, partnership updates, and quarterly financial reports offer insights into the company's capital position and runway for continued development activities.
Conference presentations at major oncology and cell therapy meetings represent another significant news category. Adicet regularly presents clinical data at events such as the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) meetings, where new data disclosures can drive substantial investor interest.
Bookmark this page to track Adicet Bio's clinical progress, financing activities, and strategic developments as the company advances its gamma delta T cell therapy platform through clinical trials.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna, currently at Vertex Pharmaceuticals, is recognized for his extensive experience in cell therapy. His previous roles include CEO of Semma Therapeutics and Global Program Head at Novartis. The addition of Dr. Sanna is expected to strengthen Adicet’s pipeline, particularly in advancing ADI-001, their allogeneic gamma delta T cell therapy. Adicet focuses on innovative cancer treatments through enhanced immune response and tumor targeting.
Adicet Bio (Nasdaq: ACET), a biotechnology firm, announced its participation in several virtual investor conferences in November and December 2020. These events include:
- H.C. Wainwright Conference on November 12, 2020, at 9:00 AM ET
- B. Riley Securities Panel on November 12, 2020, at 2:00 PM ET
- Stifel Healthcare Conference on November 17, 2020, at 3:20 PM ET
- Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 PM ET
Live audio webcasts will be available on the company's website, with archived replays for 30 days post-event.
Adicet Bio, Inc. (Nasdaq: ACET) reported its third quarter 2020 financial results on November 5, 2020. Key milestones include the merger completion with resTORbio and FDA clearance for its IND application for ADI-001, a CAR gamma-delta T cell therapy for non-Hodgkin's lymphoma. R&D expenses rose to $8.9 million, while G&A expenses increased significantly to $7.7 million due to merger-related costs, leading to a net loss of $14.8 million. The company ended the quarter with $108.1 million in cash, indicating strong liquidity for future development.
Adicet Bio (Nasdaq: ACET) announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will oversee the development of genetically-modified T cell therapies, enhancing Adicet’s approach to cancer treatment. His extensive experience in cell therapy manufacturing, including roles at KBI Biopharma and Opexa Therapeutics, positions him as a key asset for the company. This leadership addition aims to strengthen the production and clinical development of Adicet's pipeline, especially the ADI-001 therapy, which is designed for improved tumor targeting and immune response.
Adicet Bio (Nasdaq: ACET) has received FDA clearance for its Investigational New Drug (IND) application for ADI-001, an allogeneic gamma delta T cell therapy targeting CD20, aimed at treating patients with B-cell non-Hodgkin's lymphoma (NHL). This significant milestone allows the company to commence its first-in-human clinical trial to assess safety and efficacy in up to 80 patients across various U.S. cancer centers. Interim clinical data is anticipated in 2021, potentially advancing the company's innovative pipeline of CAR gamma delta T cell therapies.
Adicet Bio, a biotechnology firm specializing in gamma delta T cell therapies, announced that CEO Chen Schor and COO Stewart Abbot will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 2:30 PM ET. Investors can access a live audio webcast via Adicet's website, with an archived replay available for 30 days post-event. Adicet is focused on developing innovative cancer therapies utilizing engineered gamma delta T cells for improved tumor targeting and patient outcomes.
Adicet Bio, Inc. (Nasdaq: ACET) announced the cancellation of its proposed public offering of 4,500,000 shares, previously planned due to unfavorable market conditions. The company emphasized its strong financial position, with sufficient capital to meet goals into 2022. CEO Chen Schor highlighted anticipated milestones, including filing INDs for gamma delta CAR-T therapies and initiating Phase 1 studies for non-Hodgkin's lymphoma and other conditions. The company continues to focus on developing innovative allogeneic gamma delta T cell therapies for cancer treatments.
Adicet Bio, a clinical-stage biotechnology company, announced an underwritten public offering of 4,500,000 shares of its common stock, with a potential additional 675,000 shares option for underwriters. The offering, subject to market conditions, aims to raise capital for advancing its gamma delta T cell therapies for cancer treatment. BofA Securities, Jefferies, and SVB Leerink serve as joint book-running managers. The shares will be sold under a shelf registration statement declared effective by the SEC.
Adicet Bio, Inc. (Nasdaq: ACET) announced the grant of 195,898 non-qualified stock options to Nick Harvey, appointed as Chief Financial Officer on September 16, 2020. This option aims to incentivize Mr. Harvey's employment, vesting over four years. The first 25% will vest after one year, with the remaining 75% vesting monthly. Adicet focuses on allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response through engineered T cells.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Nick Harvey as its new Chief Financial Officer. Harvey brings over 20 years of experience in financial operations and capital markets, having previously served at Centrexion Therapeutics and Radius Health, where he played a key role in its IPO. The company's leadership expressed confidence that Harvey's expertise will support Adicet's strategic growth and advancement of its gamma delta T cell therapy platform.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
